NCT03433469View on ClinicalTrials.gov

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

July 31, 2018

Primary Completion Date

January 31, 2023

Study Completion Date

October 31, 2026

Conditions
Stage I Non-Small Cell Lung CancerStage IA Non-Small Cell Lung CancerStage IB Non-Small Cell Lung CancerStage II Non-Small Cell Lung CancerStage IIA Non-Small Cell Lung CancerStage IIB Non-Small Cell Lung CancerStage IIIA Non-Small Cell Lung Cancer
Interventions
DRUG

Osimertinib

Given PO (orally)

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (3)

80045

University of Colorado, Aurora

94143

University of California, San Francisco, San Francisco

95864

University of California, Davis, Davis

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of California, San Francisco

OTHER